Summary
The pharmacokinetics of IV meropenem (500 mg over 30 min) has been studied in 6 healthy volunteers and 26 patients with various degrees of renal impairment. Blood samples were taken at different times over 24 h in healthy subjects and 36 to 48 h in uraemic patients, and four or five urine samples were collected over 24 or 48 h. Meropenem concentrations in plasma and urine were measured by a microbiological assay.
The mean peak plasma concentration of meropenem ranged from 28 to 40 μg·ml−1 and was not affected by the degree of renal impairment. The terminal half-life of meropenem was approximately 1 h in subjects with normal kidney function and it was proportionately increased as renal function decreased. A significant linear relationship between total body clearance and creatinine clearance as well as between renal clearance and creatinine clearance was observed. The mean apparent volume of distribution at steady state was not significantly altered in uraemic patients. The mean cumulative urinary recovery of meropenem in healthy volunteers was 77% of the administered dose and it was significantly decreased in patients with renal impairment. Haemodialysis shortened the elimination half-life, from 9.7 h during the predialysis period to 1.4 h during the dialysis period. The dose of meropenem should be reduced in relation to the decrease in creatinine clearance.
Similar content being viewed by others
References
Bax RP, Bastain W, Featherstone A, Wilkinson DM, Hutchison M, Haworth SJ (1989) The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother 24 [Suppl A]: 311–320
Edwards JR, Turner PJ, Wanno PC, Withnell EW, Grindey AJ, Nairn K (1989) In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I. Antimicrob Agents Chemother 33: 215–222
Gibaldi M, Perrier D (1982) Pharmacokinetics. In: Pharmacokinetics 2nd Edition. Dekker, New York, pp 409–417
Jones RN, Aldridge KE, Allen SD, Barry AL, Fuchs PC, Gerlach EH, Pfaller MA (1989) Multicentre in vitro evaluation of SM-7338, a new carbapenem. Antimicrob Agents Chemother 33: 562–565
Neu HC, Novelli A, Chin NX (1989) In vitro activity and βlactamase stability of a new carbapenem SM-7338. Antimicrob Agents Chemother 33: 1009–1018
Norrby SR, Bjornegard B, Ferber F, Jones KH (1983) Pharmacokinetics of imipenem in healthy volunteers. J Antimicrob Chemother 12 [Suppl D]: 109–124
Sentochnik DE, Eliopoulos GM, Ferraro MJ, Moellering RC (1989) Comparative in vitro activity of SM-7338, a new carbapenem antimicrobial agent. Antimicrob Agents Chemother 33: 1232–1236
Sumia Y, Inoue M, Mitsuhashi S (1989) In vitro activity and βlactamase stability of the new carbapenem SM-7338. Eur J Clin Microbiol Infect Dis 8: 908–916
Yamaoka K, Nakagawa T, Uno T (1978) Statistical moment in pharmacokinetics. J Pharmacokinet Biopharmaceut 6: 547–558
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Leroy, A., Fillastre, J.P., Etienne, I. et al. Pharmacokinetics of meropenem in subjects with renal insufficiency. Eur J Clin Pharmacol 42, 535–538 (1992). https://doi.org/10.1007/BF00314864
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00314864